These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32232974)

  • 1. Metabolomic effects of androgen deprivation therapy treatment for prostate cancer.
    Chi JT; Lin PH; Tolstikov V; Oyekunle T; Chen EY; Bussberg V; Greenwood B; Sarangarajan R; Narain NR; Kiebish MA; Freedland SJ
    Cancer Med; 2020 Jun; 9(11):3691-3702. PubMed ID: 32232974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of low-carbohydrate diets on the metabolic response to androgen-deprivation therapy in prostate cancer.
    Chi JT; Lin PH; Tolstikov V; Oyekunle T; Alvarado GCG; Ramirez-Torres A; Chen EY; Bussberg V; Chi B; Greenwood B; Sarangarajan R; Narain NR; Kiebish MA; Freedland SJ
    Prostate; 2021 Jul; 81(10):618-628. PubMed ID: 33949711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
    Shahani S; Braga-Basaria M; Basaria S
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer.
    Saylor PJ; Karoly ED; Smith MR
    Clin Cancer Res; 2012 Jul; 18(13):3677-85. PubMed ID: 22589396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up.
    Oka R; Utsumi T; Endo T; Yano M; Kamijima S; Kamiya N; Shirai K; Suzuki H
    Int J Clin Oncol; 2016 Apr; 21(2):389-396. PubMed ID: 26296528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
    Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
    BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Changes in Androgen-Deprived Nondiabetic Men With Prostate Cancer Are Not Mediated by Cytokines or aP2.
    Gagliano-Jucá T; Burak MF; Pencina KM; Li Z; Edwards RR; Travison TG; Basaria S
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3900-3908. PubMed ID: 30032274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
    Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
    Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
    Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of hemoglobin decline in non-metastatic prostate cancer patients on androgen deprivation therapy: a matched cohort study.
    Timilshina N; Hussain S; Breunis H; Alibhai SM
    Support Care Cancer; 2011 Nov; 19(11):1815-21. PubMed ID: 20953801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
    Harrington JM; Schwenke DC; Epstein DR; Bailey DE
    Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.
    Harshman LC; Wang X; Nakabayashi M; Xie W; Valenca L; Werner L; Yu Y; Kantoff AM; Sweeney CJ; Mucci LA; Pomerantz M; Lee GS; Kantoff PW
    JAMA Oncol; 2015 Jul; 1(4):495-504. PubMed ID: 26181260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
    Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
    Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Androgen Deprivation Therapy on Overall Mortality in Prostate Brachytherapy Patients With Low Pretreatment Testosterone Levels.
    Taira AV; Merrick GS; Galbreath RW; Butler WM; Adamovich E
    Am J Clin Oncol; 2018 Jul; 41(7):667-673. PubMed ID: 27740974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
    Atkins KM; Chen MH; Wu J; Renshaw AA; Loffredo M; Kantoff PW; Small EJ; D'Amico AV
    Cancer; 2018 Apr; 124(7):1383-1390. PubMed ID: 29266181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen deprivation therapy reversibly increases endothelium-dependent vasodilation in men with prostate cancer.
    Nguyen PL; Jarolim P; Basaria S; Zuflacht JP; Milian J; Kadivar S; Graham PL; Hyatt A; Kantoff PW; Beckman JA
    J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25896892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic effects of androgen deprivation therapy.
    Choi SM; Kam SC
    Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of androgen deprivation therapy with weight management on serum aP2 and adiponectin levels in prostate cancer patients.
    Urushima H; Inomata-Kurashiki Y; Nishimura K; Sumi R; Shimomura I; Nonomura N; Ito T; Maeda K
    Aging Male; 2015 Jun; 18(2):72-6. PubMed ID: 25746209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Lipid Profiles Associated With Resistance to Androgen Deprivation Therapy in Localized Prostate Cancer.
    Lin HM; Yang X; Centenera MM; Huynh K; Giles C; Dehairs J; Swinnen JV; Hoy AJ; Meikle PJ; Butler LM; Taplin ME; Horvath LG
    JCO Precis Oncol; 2024 Jul; 8():e2400260. PubMed ID: 39074346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.